Aurora A
Aurora A kinase (AURKA) is a conserved serine/threonine kinase that primarily regulates centrosome maturation, centrosome separation, and bipolar spindle assembly during mitosis, thereby supporting accurate chromosome segregation and cell-cycle progression[1][2]. Mechanistically, AURKA functions within mitotic spindle regulatory networks and is activated through interactions with spindle-associated cofactors such as TPX2, which promotes spatial control of kinase activity during mitosis[3][4]. Through its role in microtubule organization and spindle formation, AURKA contributes to the maintenance of genomic stability, whereas dysregulated AURKA activity is associated with abnormal mitotic progression and chromosomal instability in cancer models[1][5]. In disease-relevant experimental systems, aberrant Aurora kinase signaling has been linked to tumor development and progression, supporting the use of AURKA as a molecular target in studies of mitotic control and oncogenic transformation[5][6]. Compared with related isoforms, Aurora B predominantly regulates chromosome-microtubule attachment, spindle checkpoint signaling, chromosome alignment, and cytokinesis as a core component of the chromosomal passenger complex, whereas AURKA mainly functions at centrosomes and spindle poles during early mitosis[1][2][3]. This spatial and functional distinction provides an important framework for isoform-selective experimental design and interpretation of mitotic phenotypes[1][3]. For research applications, Aurora kinase inhibitors are widely used to investigate mitotic signaling pathways and chromosome segregation mechanisms, and selective targeting strategies continue to be explored in anticancer research models[6].
References:
- [1]. Willems E, et al. The functional diversity of Aurora kinases: a comprehensive review. Cell Div. 2018 Sep 19;13:7. [Content Brief]
- [2]. Carmena M, et al. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4(11):842-854.
- [3]. Carmena M, et al. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins. Curr Opin Cell Biol. 2009 Dec;21(6):796-805. [Content Brief]
- [4]. Wikipedia.
- [5]. Pérez de Castro I, et al. Editorial: Aurora Kinases: Classical Mitotic Roles, Non-Canonical Functions and Translational Views. Front Oncol. 2017;7:48.
- [6]. Kitzen JJ, et al. Aurora kinase inhibitors. Crit Rev Oncol Hematol. 2010 Feb;73(2):99-110. [Content Brief]
-
Aurora A Related Products (104)
Related Products (104)
-
Antibodies (2)
-
Alisertib
0 ImagesSynonyms: MLN 8237Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity.
-
Reversine
0 ImagesReversine is a novel class of ATP-competitive Aurora kinase inhibitor with IC50s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.
-
Tozasertib
0 ImagesSynonyms: VX 680; MK-0457Tozasertib (VX 680; MK-0457) is an inhibitor of Aurora A/B/C kinases with Kis of 0.6, 18, 4.6 nM, respectively.
-
CCT400028
0 ImagesCat. No.: HY-181311Purity: 98.03%CCT400028 is a PROTACs-class degrader that targets the Aurora A (AURKA) kinase. CCT400028 induces ubiquitination and proteasomal degradation of target proteins by recruiting the cereblon (CRBN) E3 ubiquitin ligase. The KD values of CCT400028 against the three subtypes of human AURKA are 71 nM, 2100 nM and >10000 nM, respectively, and its IC50 against human CRBN is 6300 nM. CCT400028 is applicable to relevant research on leukemia, neuroblastoma and glioma.
-
Aurora kinase-IN-10
0 ImagesCat. No.: HY-181082CAS No.: 3053885-69-8Aurora kinase-IN-10 is an Aurora kinase inhibitor. Aurora kinase-IN-10 exhibits IC50 values of 5.94 nM and 86.06 nM against Aurora A and Aurora B, respectively. Aurora kinase-IN-10 has anti-tumor activity and can be used in the research of tumors such as triple-negative breast cancer.
-
IBPR002
0 ImagesCat. No.: HY-165369CAS No.: 1192754-38-3IBPR002 is an inhibitor of Aurora kinase A and Aurora kinase B, with IC50 values of 41 nM and 17 nM, respectively. IBPR002 disrupts the nucleation and bundling of kinetochore microtubules, impairs the bipolarity of mitotic spindles, and promotes the binding of non-phosphorylated hepatoma up-regulated protein (HURP) to microtubules derived from the mother centrosome. IBPR002 reduces tumorigenesis levels in a colorectal cancer xenograft model using athymic nude mice. IBPR002 is applicable for research related to colorectal cancer.
-
Danusertib
0 ImagesSynonyms: PHA-739358Danusertib is a pyrrolo-pyrazole and aurora kinase inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.
-
KW-2449
0 ImagesKW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABLT315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively.
-
LY3295668
0 ImagesSynonyms: AK-01LY3295668 (AK-01) is a highly specific and orally active inhibitor of Aurora-A kinase with a Ki values for AurA and AurB of 0.8 nM and 1038 nM respectively. LY3295668 can effectively inhibit the autophosphorylation of AurA, induce mitotic arrest and apoptosis. LY3295668 avoids the formation of polyploids related to AurB inhibition. LY3295668 can be used for the study of small cell lung cancer.
-
GRK6-IN-1
0 ImagesGRK6-IN-1 (Compound 18) is the inhibitor for G protein-coupled receptorkinase 6 (GRK6) with an IC50 of 3.8-8 nM. GRK6-IN-1 also inhibits GRK7, GRK5, GRK4 and GRK1 with IC50s of 6.4, 12, 22 and 52 nM, respectively. GRK6-IN-1 has the potential for the research of multiple myeloma.
-
PF 477736
0 ImagesSynonyms: PF 00477736PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a Ki of 0.49 nM, it is also a Chk2 inhibitor, with a Ki of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC50=8 (Ki), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo.
